---
schema_version: "secwatch.filing_event.v1"
accession: "0001213900-23-086937"
form_type: "8-K"
ticker: "CRMD"
cik: "0001410098"
company_name: "CorMedix Inc."
filed_at: "2023-11-14T23:59:59+00:00"
generated_at: "2026-06-08T03:19:41.008059+00:00"
event_type: "earnings"
sentiment: "neutral"
materiality_score: 0.55
calibrated_materiality_score: 0.55
confidence: "high"
source: SEC EDGAR
---

# CorMedix Q3 net loss $9.7M; FDA inspections complete, launch targeted by Q1 2024

## Summary
- Net loss $9.7M ($0.17/sh) vs $6.9M ($0.17/sh) in Q3 2022; operating expenses up 50% to $10.5M.
- Cash and short-term investments $86.6M as of Sept 30, 2023; sufficient for at least 12 months.
- FDA completed preapproval inspections at primary CMO and key suppliers; no known deficiencies.
- USPTO issued patent for DefenCath composition-of-matter (expiry April 2042).
- Commercial launch targeted before end of Q1 2024 if FDA approval received.

## SEC filing metadata
- accession: 0001213900-23-086937
- form_type: 8-K
- ticker: CRMD
- cik: 0001410098
- company_name: CorMedix Inc.
- filed_at: 2023-11-14T23:59:59+00:00
- event_type: earnings
- sentiment: neutral
- materiality_score: 0.55
- calibrated_materiality_score: 0.55
- confidence: high
- sec_items: 2.02, 9.01
- EDGAR index: https://www.sec.gov/Archives/edgar/data/1410098/000121390023086937/0001213900-23-086937-index.htm
- EDGAR primary document: https://www.sec.gov/Archives/edgar/data/1410098/000121390023086937/ea188304-8k_cormedix.htm

## Machine-readable alternates
- HTML: https://secwatch.observer/filing/0001213900-23-086937
- JSON: https://secwatch.observer/filing/0001213900-23-086937.json
- Plain text: https://secwatch.observer/filing/0001213900-23-086937.txt

## Key facts
- Earnings Releases
  CorMedix Inc. reported nine months ended September 30, 2023 results: net income net loss of $31.6 million, or $0.65 per share, EPS $0.65 per share.
  - Period: nine months ended September 30, 2023
  - Net income: net loss of $31.6 million, or $0.65 per share
  - EPS: $0.65 per share
  - Result: reported results
  source text: For the nine months ended September 30, 2023, CorMedix recorded a net loss of $31.6 million, or $0.65 per share, compared with a net loss of $21.5 million, or $0.54 per share, in the first nine months of 2022.
  evidence_url: https://www.sec.gov/Archives/edgar/data/1410098/000121390023086937/0001213900-23-086937-index.htm
- Earnings Releases
  CorMedix Inc. reported third quarter ended September 30, 2023 results: net income net loss of $9.7 million, or $0.17 per share, EPS $0.17 per share.
  - Period: third quarter ended September 30, 2023
  - Net income: net loss of $9.7 million, or $0.17 per share
  - EPS: $0.17 per share
  - Result: reported results
  source text: For the third quarter of 2023, CorMedix recorded a net loss of $9.7 million, or $0.17 per share, compared with a net loss of $6.9 million, or $0.17 per share, in the third quarter of 2022.
  evidence_url: https://www.sec.gov/Archives/edgar/data/1410098/000121390023086937/0001213900-23-086937-index.htm

This AI-assisted summary is a reading aid. Review the linked SEC EDGAR filing before relying on any specific claim.